← All trials
NCT06647407
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2024
- Primary completion
- Apr 21, 2027
- Completion date
- May 17, 2027
- First posted
- Oct 17, 2024
- Last posted
- Oct 17, 2024
- Enrollment
- 750
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanofi-AventisLead sponsor
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- acetaminophen
- serogroup b meningococcal vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- human rotavirus, live attenuated
- meningococcal groups a, b, c, w, and Y vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.